Industry News (Cancer Therapies)

Interim Phase I Data for Angiogenesis Inhibitor Announced

Published in Cancer Weekly, November 23rd, 1998

Sugen Inc., South San Francisco, California, announced interim data from its Phase I clinical trial of the SU5416 angiogenesis inhibitor.

The data were presented at the Biologic Principles for the Therapy of Human Colon Cancer Conference, held in San Diego, California, November 7, 1998, and hosted by the University of Texas M.D. Anderson Cancer Center of Houston, Texas.

In patients with advanced cancers, SU5416 appeared to be very well-tolerated with minimal side effects, researchers reported. While safety is the primary endpoint of this Phase I trial, preliminary (and, at this point, anecdotal) data indicate that SU5416 may have clinical activity...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-11-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry